<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01303068</url>
  </required_header>
  <id_info>
    <org_study_id>HRRC, 12-521</org_study_id>
    <nct_id>NCT01303068</nct_id>
  </id_info>
  <brief_title>Detection of Pseudomonas Aeruginosa in the Airways of Patients With CF</brief_title>
  <official_title>Detection of Pseudomonas. Aeruginosa in the Airways of Patients With Cystic Fibrosis Using of Aerosolized 13C-urea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of New Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of New Mexico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if inhaled urea can be used to detect the presence
      of Pseudomonas Aeruginosa in the lungs
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dose Escalation study
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective is to assess the safety of 13C urea administered by inhalation.</measure>
    <time_frame>6 hours</time_frame>
    <description>The primary endpoint is the safety of inhaled 13C urea assessed by adverse events including pulmonary findings and changes from baseline in physical examination findings, pulse oximetry results, pulmonary function test results, and vital signs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary objective is to assess the kinetics of 13C carbon dioxide production by measuring the isotopic ratio of 13C to 12C in exhaled carbon dioxide.</measure>
    <time_frame>6 hours</time_frame>
    <description>Secondary endpoints are the isotopic ratios of 13C to 12C in exhaled carbon dioxide measured with the POCone detector (Meretek Diagnostics Group of Otsuka America Pharmaceutical, Rockville, MD) at 5, 10, and 15 minutes after study drug administration.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>CF patients, 13C urea breath test kit</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CF patients with Pseudomonas infection tested with 13C urea breath test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls, 13C urea breath test kit</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy subjects using 13C urea breath test kit</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>13C urea breath test Kit</intervention_name>
    <description>20 and 50 mg, 13C urea breath test: urea nebulizer solution to detect Pseudomonas</description>
    <arm_group_label>CF patients, 13C urea breath test kit</arm_group_label>
    <arm_group_label>Healthy controls, 13C urea breath test kit</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with CF aged 18 years and above colonized with P. aeruginosa

          -  Normal subjects ages 18 and above without CF or p. aeruginosa

        Exclusion Criteria:

          -  for patients and volunteers will include the presence of asthma, allergic rhinitis,
             pregnancy, a history of gastric or duodenal ulcer, smoking, and a baseline FEV1 less
             than 60% of predicted normal value and a pulmonary exacerbation within the last 2
             weeks as defined by use of systemic antibiotic
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hengameh Raissy, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2011</study_first_submitted>
  <study_first_submitted_qc>February 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2011</study_first_posted>
  <disposition_first_submitted>December 10, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>December 10, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 13, 2016</disposition_first_posted>
  <last_update_submitted>January 12, 2016</last_update_submitted>
  <last_update_submitted_qc>January 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of New Mexico</investigator_affiliation>
    <investigator_full_name>Hengameh Raissy, Pharm.D.</investigator_full_name>
    <investigator_title>Research Associate Professor, Pediatrics</investigator_title>
  </responsible_party>
  <keyword>CF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Pseudomonas Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

